MAGE-A4 TCR-T therapy for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new type of immune therapy called MAGE-A4-directed TCR-T. It uses your own immune cells (T cells) that are modified to find and attack cancer cells that have a specific protein (MAGE-A4). It is for people with advanced solid tumors who have already tried other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old
- You have an advanced solid tumor that has spread or come back, and standard treatments have stopped working
- Your tumor tests positive for a protein called MAGE-A4 (a special marker on cancer cells)
- You have a specific blood type called HLA-A*02 (checked with a simple blood test)
- You have at least one measurable tumor on a CT scan or MRI, and you are in good enough health to undergo treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug that helps your immune system find and attack cancer cells that have a specific marker (MAGE-A1). It's for people with advanced solid tumors who have run out of standard options.
This study tests a new type of immune cell therapy that seeks out and attacks cancer cells. It is for people with advanced solid tumors who have not improved with standard treatments and whose tumors show certain markers.
This trial tests a new cell therapy called YK1101 for people with advanced solid tumors that have not responded to standard treatment. It targets a specific protein (MAGE-A4) on cancer cells and requires a matching genetic type called HLA-A*11:01.
This trial tests a personalized treatment that uses your own immune cells, modified to recognize and attack your cancer. It may help people with advanced solid tumors who have not improved with standard treatments.
This trial tests a new therapy using your own immune cells, engineered to recognize and attack cancer cells. It is for people with advanced solid tumors who have no other standard treatment options.
This study tests a new immunotherapy using specially engineered immune cells (called TCR-enhanced Vδ2 T cells) to treat blood cancers or solid tumors that haven't responded to standard treatments. The goal is to see if these cells can safely shrink tumors and improve survival.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.